SLRN
Price:
$4.7
Market Cap:
$469.10M
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatm...[Read more]
Industry
Biotechnology
IPO Date
2023-05-04
Stock Exchange
NASDAQ
Ticker
SLRN
According to Acelyrin, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 259.33M. This represents a change of -29.70% compared to the average of 368.88M of the last 4 quarters.
The mean historical Enterprise Value of Acelyrin, Inc. over the last ten years is 220.77M. The current 259.33M Enterprise Value has changed 11.65% with respect to the historical average. Over the past ten years (40 quarters), SLRN's Enterprise Value was at its highest in in the March 2023 quarter at 1.46B. The Enterprise Value was at its lowest in in the June 2022 quarter at 0.
Average
220.77M
Median
265.74M
Minimum
89.42M
Maximum
307.16M
Discovering the peaks and valleys of Acelyrin, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 243.49%
Maximum Annual Enterprise Value = 307.16M
Minimum Annual Increase = -66.35%
Minimum Annual Enterprise Value = 89.42M
Year | Enterprise Value | Change |
---|---|---|
2023 | 307.16M | 243.49% |
2022 | 89.42M | -66.35% |
The current Enterprise Value of Acelyrin, Inc. (SLRN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
220.77M
5-year avg
220.77M
10-year avg
220.77M
Acelyrin, Inc.’s Enterprise Value is
Company | Enterprise Value | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Acelyrin, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Acelyrin, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Acelyrin, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Acelyrin, Inc. (SLRN)?
What is the 3-year average Enterprise Value for Acelyrin, Inc. (SLRN)?
What is the 5-year average Enterprise Value for Acelyrin, Inc. (SLRN)?
How does the current Enterprise Value for Acelyrin, Inc. (SLRN) compare to its historical average?